Cargando…
Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT)
BACKGROUND: Genomic profiling of tumor tissue may aid in identifying predictive or prognostic gene signatures (GS) in some cancers. Retrospective gene expression profiling of melanoma and non-small-cell lung cancer led to the characterization of a GS associated with clinical benefit, including impro...
Autores principales: | Saiag, P., Gutzmer, R., Ascierto, P. A., Maio, M., Grob, J.-J., Murawa, P., Dreno, B., Ross, M., Weber, J., Hauschild, A., Rutkowski, P., Testori, A., Levchenko, E., Enk, A., Misery, L., Vanden Abeele, C., Vojtek, I., Peeters, O., Brichard, V. G., Therasse, P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035794/ https://www.ncbi.nlm.nih.gov/pubmed/27502712 http://dx.doi.org/10.1093/annonc/mdw291 |
Ejemplares similares
-
Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study
por: Gutzmer, R, et al.
Publicado: (2016) -
Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature
por: Grob, Jean-Jacques, et al.
Publicado: (2017) -
P25. Access to diagnostics: a bottleneck for immunotherapeutics development - case example of MAGE-A3 cancer immunotherapeutic
por: Lykopoulos, K, et al.
Publicado: (2014) -
Interest of corrective makeup in the management of patients in dermatology
por: Seité, S, et al.
Publicado: (2012) -
MAGE-A3-specific anticancer immunotherapy in the clinical practice
por: Brichard, Vincent G, et al.
Publicado: (2013)